Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

This was the stock's second consecutive day of losses.

Novavax (NASDAQ:NVAX), a leading player in the biopharmaceutical industry, has seen increasing institutional interest in ...

Joining Day 2 of the 2025 Bank of America Healthcare Conference. My name is Alec Stranahan, Senior Biotech Analyst covering Novavax at Bank of America. And I'm very pleased to be joined by many ...

Shares of Novavax Inc. NVAX shed 2.37% to $6.19 Tuesday, on what proved to be an all-around mixed trading session for the ...

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the first quarter ended March 31, 2025. Novavax, Inc. (Nasdaq: NVAX) today announced that it will ...

Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects. Novavax ( NASDAQ:NVAX ) First Quarter 2025 ...

Seeking Alpha assigns Novavax an A+ valuation grade. NVAX trades at 2.24× GAAP P/E (TTM) versus the Healthcare sector median of 26.15×. On an EV/Sales basis (TTM), Novavax is at 0.56× ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Department of Health and Human Services is expected to drop recommendations for routine COVID-19 vaccination for pregnant ...